Skip to main content

Table 2 Disease burden at baseline (all treatment groups combined)

From: Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis

Characteristic, mean (SD)

LEI > 0

(N = 403)a

LDI-B > 0

(N = 155)a

Integrated analysis set

(N = 679)

Pt assessment of joint pain, mm

n = 392

63.7 (19.7)

n = 151

66.9 (20.7)

n = 665

61.4 (21.1)

PtGA of disease activity, mm

n = 392

64.6 (20.9)

n = 151

68.6 (21.1)

n = 665

63.9 (20.8)

HAQ-DI total score

n = 391

1.3 (0.6)

n = 151

1.3 (0.7)

n = 664

1.2 (0.6)

EQ-5D 5L

n = 389

0.6 (0.2)

n = 151

0.5 (0.2)

n = 661

0.6 (0.2)

 EQ-5D VAS

n = 389

52.5 (19.8)

n = 151

52.6 (21.9)

n = 661

54.1 (20.9)

  1. Abbreviations: EQ-5D 5L EuroQoL-5 Dimensions 5 level, HAQ-DI Health Assessment Questionnaire-Disability Index, N number of patients in analysis population, n number of patients with non-missing data, Pt patient, PtGA patient global assessment, VAS visual analogue scale
  2. aBaseline enthesitis defined as a baseline LEI score > 0 and baseline dactylitis defined as a baseline LDI-B score > 0